CO5150223A1 - Compuestos derivados de 3,16-dihidroxi-estra-1,3,5(10)- trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contie nen - Google Patents
Compuestos derivados de 3,16-dihidroxi-estra-1,3,5(10)- trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contie nenInfo
- Publication number
- CO5150223A1 CO5150223A1 CO00007990A CO00007990A CO5150223A1 CO 5150223 A1 CO5150223 A1 CO 5150223A1 CO 00007990 A CO00007990 A CO 00007990A CO 00007990 A CO00007990 A CO 00007990A CO 5150223 A1 CO5150223 A1 CO 5150223A1
- Authority
- CO
- Colombia
- Prior art keywords
- group
- unsaturated
- saturated
- branched chain
- straight
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0055—Estrane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
Abstract
Compuestos derivados de 3,16-dihidroxi-estra-1,3,5(10)-trieno, caracterizados porque responden a la fórmula general I<EMI FILE="00007990_1" ID="1" IMF=JPEG > en la que los restos R1 a R17, independientemente entre sí, poseen los siguientes significados :R1 un átomo de halógeno, un grupo hidroxilo, un grupo metilo, un grupo trifluorometilo, un grupo metoxi, un grupo etoxi o un átomo de hidrógeno; R2 un átomo de halógeno, un grupo hidroxilo, un grupo alcoxi con hasta 6 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, o un átomo de hidrógeno;R4 un átomo de halógeno, un grupo alquilo con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, un grupo trifluormetilo o pentafluoretilo, un grupo alcoxi con hasta 6 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, o un átomo de hidrógeno;R7 un átomo de halógeno en posición a o ß, un grupo alquilo en posición a o ß, con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, un grupo alcoxi con hasta 6 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, un resto arilo o heteroarilo, en casos, dados, sustituido, o un átomo de hidrógeno; R8 un átomo de hidrógeno en posición a o ß, un grupo alquilo en posición a o ß, con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, o un grupo ciano en posición a o ß;R9 un átomo de hidrógeno en posición a o ß, un grupo metilo, etilo, trifluometilo o pentafluretilo en posición a o ß;- 2 -R11 un grupo nitrooxi en posición a o ß, un grupo hidroxilo o mercapto en posición a o ß, un átomo de halógeno en posición a o ß, un grupo clorometilo en posición a o ß, un grupo alquilo en posición a o ß; con hasta 10 átomos de carbono de cadena lineal o ramificada, saturado insaturado, en casos dados, parcial- o totalmente fluorado o un grupo alcoxi o alquiltio con hasta 6 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, un resto arilo o heterolarilo, en casos dados, sustituido, o un átomo de hidrógeno;R13 un grupo metilo, etilo, trifluormetilo o pentafluoretilo en posición a o ß;yR14 un grupo alquilo en posición a o ß con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, en casos dados parcial- o totalmente fluorado, o un átomo de hidrógeno en posición a o ß;yR15 un átomo de halógeno en posición a o ß, un grupo alquilo en posición a o ß, con hasta 10 átomos de carbono que puede estar interrumpido con uno o varios átomos de oxígeno, azufre, o con uno o varios grupos sulfóxido, sulfónicos o imino =NR15´ (R15 = átomo de hidrógeno, metilo, etilo, propilo, i-propilo), de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, o un átomo de hidrógeno;oR14 y R15 en conjunto, un grupo 14 a -15 a metileno o 14 ß -15 ß -metileno, en casos dados, sustituidos con uno o dos átomos de halógeno;R16 un grupo alquilo en posición a o ß con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado en casos dados parcial- o totalmente fluorado, un grupo trifluormetilo o pentafluormetilo un grupo cianometilo o un átomo de hidrógeno en posición a o ß;R17 un átomo de halógeno en posición a o ß, un grupo alquilo en posición a o ß, con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, un átomo de hidrógeno o un grupo hidroxilo; así corno las líneas intermitentes ------ en los anillos B, C y D, en casos dados, uno o más dobles enlaces, y las líneas onduladas ~~~ significan la disposición de los sustituyentes considerados en la posición a o ß, exceptuando los compuestos extra-1,3,5(10)-trien-3,16 a -diol, estra-1,3,5(10)-trien-3,16ß -diol, estra-1,3,5(10), 7-tetraen-3,16 a-diol, así como el estra-1,3,5(10), 7-tetraen-3,16 ß -diol, 16 a -etinil-estra-1,,3,5(10)-trien-3,16 ß -diol y 16 ß -etinil-estra-1,3,5(10)-trien-3,16 a -diol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906159A DE19906159A1 (de) | 1999-02-09 | 1999-02-09 | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5150223A1 true CO5150223A1 (es) | 2002-04-29 |
Family
ID=7897485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00007990A CO5150223A1 (es) | 1999-02-09 | 2000-02-08 | Compuestos derivados de 3,16-dihidroxi-estra-1,3,5(10)- trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contie nen |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP1144431B1 (es) |
| JP (1) | JP2002536455A (es) |
| KR (1) | KR20010101822A (es) |
| CN (1) | CN1346364A (es) |
| AR (1) | AR034392A1 (es) |
| AT (1) | ATE313553T1 (es) |
| AU (1) | AU2909500A (es) |
| BG (1) | BG105804A (es) |
| BR (1) | BR0008076A (es) |
| CA (1) | CA2359660A1 (es) |
| CO (1) | CO5150223A1 (es) |
| CZ (1) | CZ20012843A3 (es) |
| DE (2) | DE19906159A1 (es) |
| DK (1) | DK1144431T3 (es) |
| EA (1) | EA200100828A1 (es) |
| EE (1) | EE200100412A (es) |
| ES (1) | ES2255983T3 (es) |
| HK (1) | HK1046145A1 (es) |
| HU (1) | HUP0200055A3 (es) |
| IL (1) | IL144455A0 (es) |
| MX (1) | MXPA01008065A (es) |
| NO (1) | NO20013860L (es) |
| NZ (1) | NZ513409A (es) |
| PE (1) | PE20001461A1 (es) |
| PL (1) | PL350360A1 (es) |
| PT (1) | PT1144431E (es) |
| SK (1) | SK11302001A3 (es) |
| WO (1) | WO2000047603A2 (es) |
| YU (1) | YU57201A (es) |
| ZA (1) | ZA200107388B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10039199A1 (de) * | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
| DE10048634A1 (de) * | 2000-09-27 | 2002-04-18 | Jenapharm Gmbh | 19-Nor-17alpha-pregna-1,3,5(10)-trien-17beta-ole mit einem 21, 16alpha-Laktonring |
| DE10151365A1 (de) | 2001-10-17 | 2003-04-30 | Schering Ag | 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten |
| DK1365768T3 (da) * | 2001-02-27 | 2008-08-18 | Bayer Schering Pharma Ag | Anvendelse af ER-beta-selektive antagonister som contraception. |
| DE10151114A1 (de) * | 2001-10-15 | 2003-04-17 | Schering Ag | 8ß-Substituierte-11ß-aryl-estra-2,3,5(10)-trienderivate |
| DE10151363A1 (de) * | 2001-10-17 | 2003-05-08 | Schering Ag | Somatotrope Therapie |
| DE10226326A1 (de) * | 2002-06-11 | 2004-01-15 | Schering Ag | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
| US7414043B2 (en) | 2002-06-11 | 2008-08-19 | Schering Ag | 9-α-substituted estratrienes as selectively active estrogens |
| TWI392682B (zh) * | 2006-04-13 | 2013-04-11 | Sigma Tau Ind Farmaceuti | 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物 |
| TWI389917B (zh) * | 2006-04-13 | 2013-03-21 | Sigma Tau Ind Farmaceuti | 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物 |
| SE536263C2 (sv) * | 2011-12-21 | 2013-07-23 | Airqone Building Scandinavia Ab | Reningsanordning för gasmedium innefattande medel för kontrollerad tillförsel av joniserad luft |
| PL3500265T3 (pl) * | 2016-08-22 | 2024-03-11 | Or-Genix Therapeutics, Inc. | Selektywne ligandy receptora estrogenowego beta |
| WO2019041078A1 (en) * | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
| JP2021535183A (ja) * | 2018-09-07 | 2021-12-16 | トラスティーズ・オヴ・ダートマス・カレッジ | Ｃ１９骨格およびステロイドならびにそれらの使用および製造方法 |
| CN115154474A (zh) * | 2021-04-01 | 2022-10-11 | 中国人民解放军总医院 | 一种环菠萝蜜烷型三萜皂苷化合物在制备t细胞免疫抑制剂中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3079408A (en) * | 1963-02-26 | Ig-bisoxygenated iy-haloestra- | ||
| US3103524A (en) * | 1963-09-10 | Ratetraene- | ||
| GB823955A (en) * | 1955-09-01 | 1959-11-18 | Nepera Chemical Co Inc | Improvements in steroid compounds and method for manufacture of same |
| GB804789A (en) * | 1956-02-06 | 1958-11-26 | Searle & Co | 16-alkylestratriene-3,16,17-triols and derivatives thereof |
| US2779773A (en) * | 1956-05-23 | 1957-01-29 | Nepera Chemical Co Inc | Steroid 3, 16alpha-diols and process |
| US3166473A (en) * | 1962-04-12 | 1965-01-19 | Mochida Pharm Co Ltd | New esters of 1, 3, 5-estratriene-3, 16, 17-triol and novel pharmaceutical compositions containing new esters of 1, 3, 5-estratriene-3, 16, 17-triol and esters of 1, 3, 5-estratriene-3, 16, 17-triol |
| NL124324C (es) * | 1964-01-24 | |||
| FR4339M (es) * | 1965-03-29 | 1966-08-08 | ||
| FR5099M (es) * | 1966-01-12 | 1967-05-22 | ||
| US3449383A (en) * | 1967-02-16 | 1969-06-10 | Searle & Co | 17-oxygenated estra-1,3,5(10)-triene-3,11beta,16-triols,ethers and esters thereof |
| US3470159A (en) * | 1967-07-13 | 1969-09-30 | American Home Prod | Estra-1,3,5(10),7-tetraenes and process of preparation |
| CH538460A (de) * | 1969-02-27 | 1973-06-30 | Ciba Geigy Ag | Verfahren zur Herstellung eines neuen hochwirksamen Östratriols |
| FR2034569B1 (es) * | 1969-02-27 | 1973-07-13 | Ciba Geigy Ag | |
| GB1235642A (en) * | 1969-02-27 | 1971-06-16 | Ciba Geigy | A new oestratriol and a process for its manufacture |
| CH537915A (de) * | 1969-02-27 | 1973-06-15 | Ciba Geigy Ag | Verfahren zur Herstellung eines neuen Östratriols |
| US3600705A (en) * | 1969-02-27 | 1971-08-17 | Gen Electric | Highly efficient subcritically doped electron-transfer effect devices |
| US3622670A (en) * | 1969-08-22 | 1971-11-23 | American Home Prod | Method of inducing ovulation |
| IL38806A0 (en) * | 1971-03-05 | 1972-04-27 | Ciba Geigy Ag | Pharmaceutical compositions comprising estrogens and anthracene derivatives |
| US3766224A (en) * | 1971-06-03 | 1973-10-16 | Sandoz Ag | 15-methyl-substituted steroids |
| US3946052A (en) * | 1975-06-16 | 1976-03-23 | Stanford Research Institute | 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity |
| JPS5265259A (en) * | 1975-11-27 | 1977-05-30 | Takeda Chem Ind Ltd | Synthesis of 16beta-alkylestradiol or its 17-esters |
| NL7613248A (nl) * | 1976-11-26 | 1978-05-30 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroid- esters. |
| DD145919B1 (de) * | 1978-06-28 | 1982-06-30 | Kurt Ponsold | Verfahren zur herstellung von 14,1 -methylenderivaten der oestranreihe |
| SE8305596D0 (sv) * | 1983-10-12 | 1983-10-12 | Leo Ab | A selective acylation method |
| DE3510555A1 (de) * | 1985-03-21 | 1986-09-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Estriolester |
| US4705783A (en) * | 1985-06-25 | 1987-11-10 | Sri International | 9α, 11β-substituted and 11β-substituted estranes |
| HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
| SU1761760A1 (ru) * | 1990-07-02 | 1992-09-15 | Всесоюзный Эндокринологический Научный Центр Амн Ссср | Способ получени 11-нитратов 9 @ , 11 @ -диоксистероидов |
| DE4239946C2 (de) * | 1992-11-27 | 2001-09-13 | Jenapharm Gmbh | Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung |
| DE4322186A1 (de) * | 1993-07-03 | 1995-01-12 | Jenapharm Gmbh | Oral estrogen wirksame Ester des 14alpha, 15alpha-Methylen-estradiols |
| DE4326240A1 (de) * | 1993-08-02 | 1995-02-09 | Schering Ag | 15,15-Dialkyl-substituierte Derivate des Estradiols |
| US5554603A (en) * | 1993-09-17 | 1996-09-10 | The United States Of America As Represented By The Department Of Health And Human Services | Orally active derivatives of 1,3,5(10)-estratriene |
| DE4338314C1 (de) * | 1993-11-10 | 1995-03-30 | Jenapharm Gmbh | Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen |
| SE9502921D0 (sv) * | 1995-08-23 | 1995-08-23 | Astra Ab | New compounds |
| DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE19815060A1 (de) * | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
-
1999
- 1999-02-09 DE DE19906159A patent/DE19906159A1/de not_active Withdrawn
-
2000
- 2000-02-08 CO CO00007990A patent/CO5150223A1/es unknown
- 2000-02-08 PE PE2000000093A patent/PE20001461A1/es not_active Application Discontinuation
- 2000-02-09 PT PT00907539T patent/PT1144431E/pt unknown
- 2000-02-09 CN CN00803613A patent/CN1346364A/zh active Pending
- 2000-02-09 SK SK1130-2001A patent/SK11302001A3/sk unknown
- 2000-02-09 JP JP2000598520A patent/JP2002536455A/ja active Pending
- 2000-02-09 AU AU29095/00A patent/AU2909500A/en not_active Abandoned
- 2000-02-09 CZ CZ20012843A patent/CZ20012843A3/cs unknown
- 2000-02-09 EP EP00907539A patent/EP1144431B1/de not_active Expired - Lifetime
- 2000-02-09 EP EP05075149A patent/EP1580192A2/de not_active Withdrawn
- 2000-02-09 KR KR1020017009989A patent/KR20010101822A/ko not_active Application Discontinuation
- 2000-02-09 EA EA200100828A patent/EA200100828A1/ru unknown
- 2000-02-09 YU YU57201A patent/YU57201A/sh unknown
- 2000-02-09 IL IL14445500A patent/IL144455A0/xx unknown
- 2000-02-09 AR ARP000100553A patent/AR034392A1/es not_active Application Discontinuation
- 2000-02-09 AT AT00907539T patent/ATE313553T1/de not_active IP Right Cessation
- 2000-02-09 HU HU0200055A patent/HUP0200055A3/hu unknown
- 2000-02-09 WO PCT/EP2000/001073 patent/WO2000047603A2/de active IP Right Grant
- 2000-02-09 EE EEP200100412A patent/EE200100412A/xx unknown
- 2000-02-09 ES ES00907539T patent/ES2255983T3/es not_active Expired - Lifetime
- 2000-02-09 PL PL00350360A patent/PL350360A1/xx not_active Application Discontinuation
- 2000-02-09 CA CA002359660A patent/CA2359660A1/en not_active Abandoned
- 2000-02-09 BR BR0008076-4A patent/BR0008076A/pt not_active IP Right Cessation
- 2000-02-09 DK DK00907539T patent/DK1144431T3/da active
- 2000-02-09 MX MXPA01008065A patent/MXPA01008065A/es unknown
- 2000-02-09 DE DE50011908T patent/DE50011908D1/de not_active Expired - Fee Related
- 2000-02-09 NZ NZ513409A patent/NZ513409A/xx unknown
-
2001
- 2001-08-08 NO NO20013860A patent/NO20013860L/no not_active Application Discontinuation
- 2001-08-09 BG BG105804A patent/BG105804A/xx unknown
- 2001-09-06 ZA ZA200107388A patent/ZA200107388B/en unknown
-
2002
- 2002-10-17 HK HK02107553.2A patent/HK1046145A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5150223A1 (es) | Compuestos derivados de 3,16-dihidroxi-estra-1,3,5(10)- trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contie nen | |
| AR040546A1 (es) | Derivados de la 1-h- pirrolidin -2,4- diona espirociclicos, cis- alcoxisubstituidos | |
| CO5180568A1 (es) | Compuestos farmaceuticos, especialmente mutilinas, composiciones farmaceuticas que los contienen | |
| CO5280070A1 (es) | Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular | |
| AR009811A1 (es) | Compuestos herbicidas, proceso para su produccion, proceso para la produccion de intermediarios, compuestos intermediarios para su exclusivo usoen dicho proceso, composicion que tiene actividad herbicida selectiva y proceso para el control selectivo de malas hierbas y gramineas en cultivos de planta | |
| CO5150150A1 (es) | 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales | |
| CO5261551A1 (es) | Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas | |
| CO5180557A1 (es) | Derivados de 1,4-diazabiciclo[3.2.2]nonan-4-carboxilatos y carboxamidas y sus composiciones farmaceuticas . | |
| ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
| HK1126183A1 (en) | Polynucleotide labelling reagent | |
| CO5261539A1 (es) | Compuestos farmaceuticamente activos | |
| CO5310534A1 (es) | Nuevos derivados de androstano anti-inflamatorios | |
| AR029773A1 (es) | Un metodo para inhibir la polimerizacion prematura de monomeros etilenicamente insaturados y una composicion de un monomero etilenicamente insaturado preparada con el mismo | |
| CO5690130A1 (es) | Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento del snc | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| BR0109263A (pt) | Polìmeros de resistência elevada e vedantes aeroespaciais desses | |
| CO5160253A1 (es) | Complejo de 1,4-benzodiazepinas sustituidas y sulfobutileter -7-ciclodextrina o 2-hidroxipropil-b-ciclodextrina . | |
| DE60140748D1 (de) | Thiazol-derivate zur verwendung als entzündungshemmende mittel | |
| CO5320599A1 (es) | Inhibidores no peptidilicos de la union a las celulas depen dientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
| ES2179005T3 (es) | Compuesto de cromeno. | |
| PE20001516A1 (es) | Compuestos triciclicos como inhibidores de la farnesil transferasa | |
| HUP0100978A2 (hu) | Benzotiadiazolok és származékaik, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| CO5180544A1 (es) | Derivados de mononitrato de tiocarboxilatos y piridil-mercapto-carboxilatos de isosorbida | |
| HRP20090018T3 (en) | Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents | |
| CO5130006A1 (es) | Compuestos de pirazina |